<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04323436</url>
  </required_header>
  <id_info>
    <org_study_id>CINC280J12201</org_study_id>
    <secondary_id>2019-003097-11</secondary_id>
    <nct_id>NCT04323436</nct_id>
  </id_info>
  <brief_title>Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations</brief_title>
  <official_title>A Double-blind, Placebo Controlled, Randomized, Phase II Study Evaluating the Efficacy and Safety of Capmatinib and Spartalizumab vs Capmatinib and Placebo as 1st Line Treatment for Advanced NSCLC Patients With MET exon14 Skipping Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A double-blind, placebo controlled, randomized, phase II study evaluating the efficacy and&#xD;
      safety of capmatinib (INC280) and spartalizumab (PDR001) combination therapy versus&#xD;
      capmatinib and placebo as first line treatment for locally advanced or metastatic non-small&#xD;
      cell lung cancer (NSCLC) patients with MET exon 14 skipping (METΔex14) mutations&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of capmatinib in combination&#xD;
      with spartalizumab in treatment naive patients with EGFR wild-type, ALK rearrangement&#xD;
      negative advanced NSCLC, harboring METΔex14 mutations.&#xD;
&#xD;
      A run-in part (Part 1) will be conducted to determine the anti-tumor activity and safety of&#xD;
      capmatinib in combination with spartalizumab. Upon review of safety data and confirmation of&#xD;
      anti-tumor activity in Part 1, the randomized part (Part 2) will be initiated to compare the&#xD;
      efficacy and safety of capmatinib plus spartalizumab to capmatinib plus placebo.&#xD;
&#xD;
      Combined treatment of METΔex14 mutated NSCLC with capmatinib and spartalizumab is expected to&#xD;
      result in improved efficacy compared to each single agent due to direct targeting of an&#xD;
      oncogenic driver (MET) as well as more efficient stimulation of an anti-tumor immune response&#xD;
      than with PD-1 blockade alone.&#xD;
&#xD;
      The study enrollment was halted on 28-Jul-2021 per sponsor's decision. The enrollment halt&#xD;
      decision was based on lack of tolerability observed in capmatinib and spartalizumab&#xD;
      combination treatment in the run-in part (Part 1) of the trial.&#xD;
&#xD;
      Following the study enrollment halt during Part 1 (Run in Part), Part 2 will not be&#xD;
      initiated.&#xD;
&#xD;
      Immediately following the enrollment halt:&#xD;
&#xD;
        -  All ongoing subjects were discontinued from spartalizumab treatment and continue to&#xD;
           receive single agent capmatinib, given the proven tolerability and efficacy of&#xD;
           capmatinib monotherapy in this study indication.&#xD;
&#xD;
        -  Enrolled subjects who had not started study treatment were to receive capmatinib single&#xD;
           agent treatment from the start&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 19, 2020</start_date>
  <completion_date type="Anticipated">January 13, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 13, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Run-in part: single arm, open-label.&#xD;
Randomized part: two-arms parallel assignment, double-blinded, placebo control</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate by Investigator assessment as per RECIST 1.1</measure>
    <time_frame>2.5 years</time_frame>
    <description>Run-in part To evaluate the anti-tumor activity of capmatinib in combination with spartalizumab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression Free survival (PFS) by BIRC as per RECIST 1.1</measure>
    <time_frame>6 years</time_frame>
    <description>Randomized part To compare the efficacy of capmatinib in combination with spartalizumab versus capmatinib plus placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AE) and Serious Adverse events (SAE) incidence</measure>
    <time_frame>2.5 years</time_frame>
    <description>Run-in part To assess safety of capmatinib in combination with spartalizumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with dose interruptions, reductions, and dose intensity</measure>
    <time_frame>2.5 years</time_frame>
    <description>Run-in part To assess tolerability of capmatinib in combination with spartalizumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy measurements per RECIST 1.1 : Disease Control Rate (DCR) by investigator asessment</measure>
    <time_frame>2.5 years</time_frame>
    <description>Run-in part Disease Control Rate (DCR) to further evaluate the anti-tumor activity of capmatinib in combination with spartalizumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy measurements per RECIST 1.1 : Progression Free Survival (PFS) by investigator assessment</measure>
    <time_frame>2.5 years</time_frame>
    <description>Run in part Progression Free Survival (PFS) to further evaluate the anti-tumor activity of capmatinib in combination with spartalizumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Cmax</measure>
    <time_frame>2.5 years</time_frame>
    <description>Run-in part To evaluate the PK of capmatinib and spartalizumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Tmax</measure>
    <time_frame>2.5 years</time_frame>
    <description>Run-in part To evaluate the PK of capmatinib and spartalizumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): AUClast</measure>
    <time_frame>2.5 years</time_frame>
    <description>Run-in part To evaluate the PK of capmatinib and spartalizumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): AUCtau</measure>
    <time_frame>2.5 years</time_frame>
    <description>Run-in part To evaluate the PK of capmatinib and spartalizumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>12 years</time_frame>
    <description>Randomized part To compare overall survival of capmatinib in combination with spartalizumab versus capmatinib plus placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AE) and Serious Adverse events (SAE) incidence</measure>
    <time_frame>6 years</time_frame>
    <description>Randomized part To assess safety of capmatinib in combination with spartalizumab versus capmatinib plus placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with dose interruptions, reductions, and dose intensity</measure>
    <time_frame>6 years</time_frame>
    <description>Randomized part To assess tolerability of capmatinib in combination with spartalizumab versus capmatinib plus placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy measurements per RECIST 1.1: Progression Free Survival (PFS) by investigator assessment</measure>
    <time_frame>6 years</time_frame>
    <description>Randomized part Progression Free Survival (PFS) to further evaluate the anti-tumor activity of capmatinib in combination with spartalizumab versus capmatinib plus placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy measurements per RECIST 1.1: Disease Control Rate (DCR) by BIRC and investigator assessment</measure>
    <time_frame>6 years</time_frame>
    <description>Randomized part Disease Control Rate (DCR) to further evaluate the anti-tumor activity of capmatinib in combination with spartalizumab versus capmatinib plus placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy measurements per RECIST 1.1: Duration of Response (DOR) by BIRC and investigator assessment</measure>
    <time_frame>6 years</time_frame>
    <description>Randomized part Duration of Response (DOR) to further evaluate the anti-tumor activity of capmatinib in combination with spartalizumab versus capmatinib plus placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy measurements per RECIST 1.1: Overall Response Rate (ORR) by BIRC and investigator assessment</measure>
    <time_frame>6 years</time_frame>
    <description>Randomized part Overall Response Rate (ORR) to further evaluate the anti-tumor activity of capmatinib in combination with spartalizumab versus capmatinib plus placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy measurements per RECIST 1.1: Time to Response (TTR) by BIRC and investigator assessment</measure>
    <time_frame>6 years</time_frame>
    <description>Randomized part Time to Response (TTR) To further evaluate the anti-tumor activity of capmatinib in combination with spartalizumab versus capmatinib plus placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in EORTC QLQ-C30 questionnaires</measure>
    <time_frame>6 years</time_frame>
    <description>Randomized part To evaluate patient reported outcomes of capmatinib in combination with spartalizumab versus capmatinib plus placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in EQ-LC13 questionnaires</measure>
    <time_frame>6 years</time_frame>
    <description>Randomized part To evaluate patient reported outcomes of capmatinib in combination with spartalizumab versus capmatinib plus placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in EQ-5D-5L questionnaires</measure>
    <time_frame>6 years</time_frame>
    <description>Randomized part To evaluate patient reported outcomes of capmatinib in combination with spartalizumab versus capmatinib plus placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to definitive 10 points deterioration symptom scores for pain in chest, coughing and dyspnea per QLQ-LC13 questionnaire</measure>
    <time_frame>6 years</time_frame>
    <description>Randomized part To evaluate patient reported outcomes of capmatinib in combination with spartalizumab versus capmatinib plus placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Cmax</measure>
    <time_frame>6 years</time_frame>
    <description>Randomized part To evaluate the PK of capmatinib and spartalizumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Tmax</measure>
    <time_frame>6 years</time_frame>
    <description>Randomized part To evaluate the PK of capmatinib and spartalizumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): AUCtau</measure>
    <time_frame>6 years</time_frame>
    <description>Randomized part To evaluate the PK of capmatinib and spartalizumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): AUClast.</measure>
    <time_frame>6 years</time_frame>
    <description>Randomized part To evaluate the PK of capmatinib and spartalizumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antidrug antibodies (ADA) prevalence at baseline on treatment with spartalizumab</measure>
    <time_frame>6 years</time_frame>
    <description>Randomized part To evaluate the prevalence of immunogenicity of spartalizumab in combination with capmatinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antidrug antibodies (ADA) incidence on treatment with spartalizumab</measure>
    <time_frame>6 years</time_frame>
    <description>Randomized part To evaluate the incidence of immunogenicity of spartalizumab in combination with capmatinib</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>Run-in part</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>capmatinib in combination with spartalizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Randomized part - Arm 1 spartalizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>capmatinib in combination with spartalizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Randomized part - Arm 2 placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>capmatinib in combination with placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spartalizumab</intervention_name>
    <description>Concentrate for solution for infusion</description>
    <arm_group_label>Randomized part - Arm 1 spartalizumab</arm_group_label>
    <arm_group_label>Run-in part</arm_group_label>
    <other_name>PDR001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capmatinib</intervention_name>
    <description>Film-coated tablet</description>
    <arm_group_label>Randomized part - Arm 1 spartalizumab</arm_group_label>
    <arm_group_label>Randomized part - Arm 2 placebo</arm_group_label>
    <arm_group_label>Run-in part</arm_group_label>
    <other_name>INC280</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>spartalizumab placebo</intervention_name>
    <description>dextrose 5% in water (D5W) for infusion</description>
    <arm_group_label>Randomized part - Arm 2 placebo</arm_group_label>
    <other_name>PDR001 placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed locally advanced or metastatic NSCLC which is EGFR wild-type,&#xD;
             ALK rearrangement negative and METΔex14 mutated&#xD;
&#xD;
          -  No prior systemic therapy for advanced/metastatic disease (neo-adjuvant/adjuvant&#xD;
             treatment completed &gt; 12 months before relapse are permitted)&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1&#xD;
&#xD;
          -  Measurable disease as per RECIST 1.1&#xD;
&#xD;
          -  Known PD-L1 tumor expression status (applicable to Randomized part 2 only)&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with a PD-1/PD-L1 inhibitor, MET inhibitor or HGF inhibitor&#xD;
&#xD;
          -  Presence of symptomatic CNS metastases or requiring local CNS-directed therapy&#xD;
             (radiotherapy or surgery), or increasing doses of corticosteroids 2 weeks prior to&#xD;
             study entry&#xD;
&#xD;
          -  Impaired cardiac function or clinically significant cardiac disease&#xD;
&#xD;
          -  Presence or history of interstitial lung disease, non-infectious pneumonitis or&#xD;
             interstitial pneumonitis, including clinically significant radiation pneumonitis&#xD;
&#xD;
          -  History of allogenic bone marrow or solid organ transplant&#xD;
&#xD;
          -  Radiotherapy to lung fields ≤ 4 weeks or to any other anatomic site ≤ 2 weeks prior to&#xD;
             start of study treatment (palliative radiotherapy for bone lesions is allowed)&#xD;
&#xD;
        Other inclusion and exclusion criteras may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Massachusetts General Hospital Liver and Kidney TX</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pierre Benite Cedex</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gerlingen</city>
        <zip>70839</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koeln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bologna</city>
        <state>BO</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Osaka Sayama</city>
        <state>Osaka</state>
        <zip>589 8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucia</state>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 23, 2020</study_first_submitted>
  <study_first_submitted_qc>March 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2020</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>capmatinib</keyword>
  <keyword>spartalizumab</keyword>
  <keyword>MET mutation</keyword>
  <keyword>EGFR wild-type</keyword>
  <keyword>ALK negative mutation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spartalizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

